Sponsors (18)
The bill expands Medicaid coverage of genomic sequencing for children—improving diagnosis and the potential for targeted care—while creating short-term state cost pressures and implementation risks (workforce, prior authorization, and payment disputes) that could delay or unevenly limit access.
Medicaid-enrolled children suspected of genetic disorders gain covered access to whole-genome/whole-exome sequencing (WGS/WES) as a first-tier test, increasing diagnostic rates and opportunities for earlier, condition-specific care.
Families can receive more targeted follow-up and treatment because the bill requires reporting on services and outcomes triggered by WGS/WES, supporting better clinical decision-making and quality measurement.
Hospitals, labs, and clinicians get clearer reimbursement incentives because states must pay separately for WGS/WES, which may increase provider willingness to offer testing and improve access.
State Medicaid programs may face higher short-term costs to cover WGS/WES separately, potentially increasing state expenditures, forcing budget trade-offs, or pressuring state finances.
Implementation may strain the genetic counseling workforce and laboratory capacity, causing delays, backlogs, or geographically uneven access to testing and follow-up care.
States could respond to new coverage requirements by tightening prior authorization or utilization controls, producing delays or barriers to timely testing despite formal coverage.
Based on analysis of 2 sections of legislative text.
Introduced January 15, 2026 by Scott Peters · Last progress January 15, 2026
Requires Medicaid to cover and separately pay for whole genome sequencing (WGS) and whole exome sequencing (WES) as first‑tier tests for children suspected of having a genetic disorder, rare disease, or unexplained condition (including congenital anomalies, global developmental delay, or intellectual disability). Defines WGS/WES to include sequencing plus analysis, interpretation, and reporting, and allows sequencing of first‑degree relatives when primarily for the child’s diagnosis. Directs the Department of Health and Human Services to convene stakeholders and publish a public report within two years on State payment amounts and utilization/outcomes for children on Medicaid, and directs the Government Accountability Office to analyze stakeholder feedback, prior authorization impacts, workforce and reimbursement issues for genetic counselors, and fee alignment with Medicare, with a report due within two years. The coverage and payment changes take effect January 1, 2027.